Low-dose colchicine therapy can favorably remodel coronary plaque following acute coronary syndrome (ACS), reducing one of the major predictors of future cardiovascular events, according to a new study in JACC: Cardiovascular Imaging.

Cardiovascular research has traditionally focused on hard clinical endpoints such as markers of disease progression, adverse events and death. But now researchers are calling for more studies that incorporate the viewpoints of patients and caregivers, both in trial design and execution and in measuring outcomes like quality of life, time off work, out-of-pocket expense and caregiver burden.

It’s well-established that cholesterol-lowering PCSK9 inhibitors (PCSK9i) are a pricey addition to any heart patient’s medication regimen, climbing to more than $14,000 per year at retail value and $5,000 in out-of-pocket costs—but they are effective.

Women and minorities experience a higher risk of recurrent ischemic events than white men following everolimus-eluting stent implantation, a JAMA Cardiology study recently found.

Clinical guidelines don’t recommend valve replacement for patients with severe aortic stenosis (AS) demonstrating normal flow and low gradients. But maybe they should, according to new research published in JACC: Cardiovascular Imaging.